poly(ADP-ribose) polymerase family member 3Genealiases: ADPRT3 · ADPRTL2 · ADPRTL3 · ARTD3 · IRT1 · PADPRT-3
Q-omics provides the consensus-scored PARP3 profile across patient tissues and cancer cell-line models. PARP3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, PARP3 is differentially expressed in 12, with the highest sampling consensus in KIRC. Additionally, PARP3 protein abundance shows 29,574 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight KIRP, KIRC, and PDAC as cancer lineages where PARP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for PARP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes PARP3 survival associations across molecular data types. PARP3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (4) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible PARP3 RNA expression–survival associations across cancer types. High PARP3 expression shows unfavorable associations in LAML and KICH, but favorable associations in KIRP, BRCA, BLCA and COAD. The KIRP Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for PARP3 RNA expression.
This table summarizes PARP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for PARP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. PARP3 shows lower tumor expression in KIRC, THCA, LUSC and BRCA and higher tumor expression in LIHC and CHOL. The KIRC box plot shows higher PARP3 RNA expression in normal versus tumor tissue (log2 FC = −0.577, t-test p < 0.001).
This table shows molecular features associated with PARP3 in patient tissues and cancer cell lines. In patient samples, PARP3 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, PARP3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Lymphoma and BONE.
